Biocryst Pharmaceuticals annual capital expenditures (capex)
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Biocryst Pharmaceuticals Capital Expenditures (CapEx) Growth & History (BCRX)
Biocryst Pharmaceuticals's capital expenditures (capex) was $2.5M for fiscal 2025.
View full Biocryst Pharmaceuticals company overviewBiocryst Pharmaceuticals annual capital expenditures (capex) history
| Fiscal year | Period ended | Capital expenditures (CapEx) | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $2.5M | $1.3M | +119.57% |
| 2024 | 2024-12-31 | $1.1M | −$1.0M | −48.15% |
| 2023 | 2023-12-31 | $2.2M | $817,000 | +60.47% |
| 2022 | 2022-12-31 | $1.4M | −$1.0M | −43.35% |
| 2021 | 2021-12-31 | $2.4M | $1.9M | +364.01% |
| 2020 | 2020-12-31 | $514,000 | $171,000 | +49.85% |
| 2019 | 2019-12-31 | $343,000 | −$23,000 | −6.28% |
| 2018 | 2018-12-31 | $366,000 | $38,000 | +11.59% |
| 2017 | 2017-12-31 | $328,000 | −$4.9M | −93.78% |
| 2016 | 2016-12-31 | $5.3M | $155,000 | +3.03% |
| 2015 | 2015-12-31 | $5.1M | $5.0M | +4732.08% |
| 2014 | 2014-12-31 | $106,000 | $76,000 | +253.33% |
| 2013 | 2013-12-31 | $30,000 | −$83,000 | −73.45% |
| 2012 | 2012-12-31 | $113,000 | $58,000 | +105.45% |
| 2011 | 2011-12-31 | $55,000 | −$270,000 | −83.08% |
| 2010 | 2010-12-31 | $325,000 | −$279,000 | −46.19% |
| 2009 | 2009-12-31 | $604,000 | — | — |
Biocryst Pharmaceuticals quarterly capital expenditures (capex)
Q3.10
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q3.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Capital expenditures (CapEx) | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $209,000 | $30,000 | +16.76% |
| Q1 2026 | 2026-03-31 | $403,000 | $260,000 | +181.82% |
| Q4 2025 | 2025-12-31 | $802,000 | $127,000 | +18.81% |
| Q3 2025 | 2025-09-30 | $1.3M | $1.3M | +2177.97% |
| Q2 2025 | 2025-06-30 | $179,000 | $24,000 | +15.48% |
| Q1 2025 | 2025-03-31 | $143,000 | −$92,000 | −39.15% |
| Q4 2024 | 2024-12-31 | $675,000 | $121,000 | +21.84% |
| Q3 2024 | 2024-09-30 | $59,000 | −$928,000 | −94.02% |
| Q2 2024 | 2024-06-30 | $155,000 | −$312,000 | −66.81% |
| Q1 2024 | 2024-03-31 | $235,000 | $75,000 | +46.88% |
| Q4 2023 | 2023-12-31 | $554,000 | $28,000 | +5.32% |
| Q3 2023 | 2023-09-30 | $987,000 | $812,000 | +464.00% |
| Q2 2023 | 2023-06-30 | $467,000 | $223,000 | +91.39% |
| Q1 2023 | 2023-03-31 | $160,000 | −$246,000 | −60.59% |
| Q4 2022 | 2022-12-31 | $526,000 | −$582,000 | −52.53% |
| Q3 2022 | 2022-09-30 | $175,000 | −$190,000 | −52.05% |
| Q2 2022 | 2022-06-30 | $244,000 | −$569,000 | −69.99% |
| Q1 2022 | 2022-03-31 | $406,000 | $307,000 | +310.10% |
| Q4 2021 | 2021-12-31 | $1.1M | $953,000 | +614.84% |
| Q3 2021 | 2021-09-30 | $365,000 | $193,000 | +112.21% |
| Q2 2021 | 2021-06-30 | $813,000 | $742,000 | +1045.07% |
| Q1 2021 | 2021-03-31 | $99,000 | −$17,000 | −14.66% |
| Q4 2020 | 2020-12-31 | $155,000 | $75,000 | +93.75% |
| Q3 2020 | 2020-09-30 | $172,000 | $89,000 | +107.23% |
| Q2 2020 | 2020-06-30 | $71,000 | −$16,000 | −18.39% |
| Q1 2020 | 2020-03-31 | $116,000 | $23,000 | +24.73% |
| Q4 2019 | 2019-12-31 | $80,000 | −$24,000 | −23.08% |
| Q3 2019 | 2019-09-30 | $83,000 | $42,000 | +102.44% |
| Q2 2019 | 2019-06-30 | $87,000 | −$99,000 | −53.23% |
| Q1 2019 | 2019-03-31 | $93,000 | $58,000 | +165.71% |
| Q4 2018 | 2018-12-31 | $104,000 | −$11,000 | −9.57% |
| Q3 2018 | 2018-09-30 | $41,000 | −$148,000 | −78.31% |
| Q2 2018 | 2018-06-30 | $186,000 | $165,000 | +785.71% |
| Q1 2018 | 2018-03-31 | $35,000 | $32,000 | +1066.67% |
| Q4 2017 | 2017-12-31 | $115,000 | $114,000 | +11400.00% |
| Q3 2017 | 2017-09-30 | $189,000 | $10,000 | +5.59% |
| Q2 2017 | 2017-06-30 | $21,000 | −$1.8M | −98.86% |
| Q1 2017 | 2017-03-31 | $3,000 | −$3.3M | −99.91% |
| Q4 2016 | 2016-12-31 | $1,000 | −$4.0M | −99.98% |
| Q3 2016 | 2016-09-30 | $179,000 | $37,000 | +26.06% |
| Q2 2016 | 2016-06-30 | $1.8M | $1.5M | +398.37% |
| Q1 2016 | 2016-03-31 | $3.3M | $2.7M | +476.99% |
| Q4 2015 | 2015-12-31 | $4.0M | $4.0M | +6124.62% |
| Q3 2015 | 2015-09-30 | $142,000 | $108,000 | +317.65% |
| Q2 2015 | 2015-06-30 | $369,000 | $369,000 | — |
| Q1 2015 | 2015-03-31 | $565,000 | $558,000 | +7971.43% |
| Q4 2014 | 2014-12-31 | $65,000 | — | — |
| Q3 2014 | 2014-09-30 | $34,000 | $34,000 | — |
| Q2 2014 | 2014-06-30 | $0 | — | — |
| Q1 2014 | 2014-03-31 | $7,000 | — | — |
| Q3 2013 | 2013-09-30 | $0 | −$6,000 | — |
| Q4 2012 | 2012-12-31 | $2,000 | $1,000 | +100.00% |
| Q3 2012 | 2012-09-30 | $6,000 | $5,000 | +500.00% |
| Q2 2012 | 2012-06-30 | $40,000 | $17,000 | +73.91% |
| Q1 2012 | 2012-03-31 | $69,000 | $39,000 | +130.00% |
| Q4 2011 | 2011-12-31 | $1,000 | — | — |
| Q3 2011 | 2011-09-30 | $1,000 | −$64,000 | −98.46% |
| Q2 2011 | 2011-06-30 | $23,000 | — | — |
| Q1 2011 | 2011-03-31 | $30,000 | — | — |
| Q3 2010 | 2010-09-30 | $65,000 | — | — |
Biocryst Pharmaceuticals capital expenditures (capex) trends
Over the last five fiscal years, Biocryst Pharmaceuticals's capital expenditures (capex) increased from $514,000 to $2.5M, a change of $2.0M. The latest reported quarter, Q2 2026, shows $209,000.
About the metric
What capital expenditures (CapEx) mean
Capital expenditures, commonly called CapEx, are cash investments in long-lived assets such as property, plants, equipment, infrastructure, and productive software. CapEx can support future growth or maintain existing operations, but it reduces current-period free cash flow.
Calculation and source
SEC-reported capital expenditures
TickerStat standardizes cash payments for property, plant, equipment, and other productive assets reported in company SEC filings. When a filer reports separate qualifying CapEx components instead of a total, those components are combined for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Biocryst Pharmaceuticals source filings ↗